Cooper Companies Q2 Revenue Up 8% to $1.08B, EPS Jumps 26%
COO•Cooper Companies delivered record Q2 revenue of $1.08 billion, up 8%, with non-GAAP EPS rising 26% to $1.21, driven by 8% sales gains at both CooperSurgical and CooperVision. It cut CooperVision organic growth guidance to 3.5%-4.5% on Asia softness, warned of margin declines from FX and absorbed a $271.6 million litigation charge.
1. Q2 Financial Results
Cooper Companies posted record Q2 revenue of $1.08 billion, an 8% year-over-year increase, driven by 8% sales growth in both CooperSurgical and CooperVision. Non-GAAP earnings per share rose 26% to $1.21, supported by robust demand in fertility products and strong performance across major regions.
2. Guidance Revision and Margin Outlook
The company cut CooperVision's full-year organic growth forecast to 3.5%–4.5% due to softer markets in Japan and China. It also expects gross margins to decline year-over-year, citing unfavorable foreign exchange and higher costs from tariffs and freight.
3. Litigation Impact and Cash Flow
The resolution of fertility-business litigation related to a December 2023 embryo culture media recall resulted in a net charge of $271.6 million. Despite this, Cooper Companies generated strong free cash flow, reinforcing confidence in its cash generation capacity.
4. Strategic Review and Capital Allocation
Interest in a potential sale of CooperSurgical covers both the entire business and individual units, with focus currently on selling the whole division. The company signaled plans to increase share repurchases going forward after a conservative approach earlier in the year.
